IMMUNOREACT 9 metachronous rectal cancers have high HLA-ABC expression on healthy epithelium but a lower infiltration of CD3+ T cells than primary lesions
Beatrice Salmaso(Ospedale Santa Maria della Misericordia di Rovigo), Alessandra Piccioli, Roberta Salmaso, Giulia Becherucci(University of Padua), Maurizio Zizzo(Azienda Sanitaria Unità Locale di Reggio Emilia), Ivana Cataldo(Ospedale SS. Annunziata), Angelo Paolo Dei Tos(University of Padua), Giulia Pozza(University of Padua), Melania Scarpa(University of Padua), Daunia Verdi(ASL Roma), Francesca Bergamo(Istituto Oncologico Veneto), Cesare Ruffolo(Ca' Foncello Hospital), Astghik Stepanyan(University of Padua), Mario Godina(ASL Roma), Vittorina Zagonel(Istituto Oncologico Veneto), Marco Massani(AULSS 2 Marca Trevigiana), Silvia Negro(University of Padua), Stefano Brignola(University of Padua), Valentina Chiminazzo(University of Padua), Roberto Merenda(Ospedale Civile di Venezia), Tommaso Stecca(Ca' Foncello Hospital), Giorgio Rivella(University of Padua), Antonio Scapinello(Istituto Oncologico Veneto), Luca Dal Santo(University of Padua), Pierluigi Pilati(Istituto Oncologico Veneto), Darío Gregori(University of Padua), Gianluca Businello(University of Padua), Luca Saadeh(University of Padua), Gaya Spolverato(University of Padua), Federico Scognamiglio(University of Padua), Andromachi Kotsafti(Istituto Oncologico Veneto), Luca Facci(University of Padua), Ottavia De Simoni(Istituto Oncologico Veneto), Isabella Mondi(Ospedale di Mirano), Giovanni Pirozzolo(Ottawa Hospital), Alfonso Recordare(Ca' Foncello Hospital), Imerio Angriman, Boris Franzato(Istituto Oncologico Veneto), Giovanni Bordignon(AULSS 2 Marca Trevigiana), Chiara Vignotto(University of Padua), Isacco Maretto(University of Padua), Vincenza Guzzardo(University of Padua), Anna Pozza(University of Padua), Corrado Da Lio(Ospedale di Mirano), Valerio Pellegrini(University of Padua), Ceccon Carlotta(University of Padua), Francesco Marchegiani, Laurino Licia(Azienda Ospedale - Università Padova), Silvio Guerriero
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k